FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

gton, D.C. 20549		OΝ	٠

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									
	OMB Number: Estimated average burden									

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
J	obligations may continue. See
	Instruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar	nd Address of	Reporting Person*						ker or Trading	,			ationship of		Persor	n(s) to Issue	r	
Robbins Andrew R				2	Cogent Biosciences, Inc. [ COGT ]							(Check all applicable)  X Director 10% Owner				ner	
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 01/23/2024						X	below)			Other (sp	pecify	
C/O COGENT BIOSCIENCES, INC.												President and CEO					
275 WYMAN STREET, 3RD FLOOR				4	4. If Amendment, Date of Original Filed (Month/Day/Year)						- 1	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person					
(Street)	AM N	1A	02451	L								Form file	d by More	than (	One Reportin	ng Person	
WALITIAWI WIA 02431					Rule 10b5-1(c) Transaction Indication												
(City)	(S	State)	(Zip)	]	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date			2. Transact Date (Month/Day	Execution Date		e, Transaction Disposed Code (Instr.		rities Acquired (A) or ed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		Form:	Direct Indirect Etr. 4)	. Nature of ndirect seneficial ownership nstr. 4)			
									Amoun	t (A)	or Price	Transactio (Instr. 3 an				1150. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	e es ally g	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (Right to Buy)	\$4.63	01/23/2024		A		1,100,000		(1)	01/23/2034	Common Stock	1,100,000	\$0.00	1,100,	000	D		

## Explanation of Responses:

1. This stock option shall vest in equal monthly installments over a four year period.

/s/ Evan D. Kearns, Attorney-in-01/25/2024

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.